Nanna is a General Parter at Forbion and has been part of the team since 2021. She focuses on Forbion's Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies, where she is responsible for deal sourcing and investment management.
Successful investments include Capstan Therapeutics, where Nanna was on the board until its acquisition by AbbVie for $2.1Bn in August 2025; Inversago, where she was on the board until its acquisition by Novo Nordisk for up to $1.1Bn in August 2023, and Numab Therapeutics, which spun out and divested Yellow Jersey Therapeutics to J&J for $1.25Bn in July 2024.
Prior to joining Forbion, Nanna was part of the Venture Investment team of Novo Holdings, focusing on late-stage biopharma investments across Europe. During her 10 years at Novo Holdings, Nanna was involved in numerous successful European growth stage investments and IPOs, including NBE Therapeutics GmbH, acquired by Boehringer Ingelheim, ReViral Ltd., acquired by Pfizer, LAVA Therapeutics N.V. (NASDAQ: LVTX), Orphazyme A/S (ORPHA.CO; ORPH), Inventiva S.A. (NASDAQ: IVA – Euronext Paris: IVA), ObsEva SA (NASDAQ: OBSV; SIX: OBSN), Numab Therapeutics AG and Nodthera Limited.
Nanna began her career in venture capital at Apposite Capital and worked as a Senior Business Analyst at Cancer Research UK. Nanna holds an MBA from the University of Cambridge, a PhD in Neuroscience from University College London, and a BA in Physiology and Psychology from the University of Oxford.
The Forbion platform provides an amazing scale and depth of expertise, which enables me to work with some of the most exciting companies and entrepreneurs in our industry.
Portfolio
Companies worked on by Nanna Lüneborg
